Eli Lilly retains up ophthalmic gene remedy push with $475m MeiraGTx deal
Eli Lilly has agreed to a $475m licensing take care of MeiraGTx, marking the second eye illness gene remedy guess by the drugmaker in as many months.
Eli Lilly can pay UK-based MeiraGTx $75m upfront for world unique rights to AAV-AIPL1, a gene remedy in growth for a uncommon type of inherited blindness, together with entry to additional gene remedy applied sciences developed by the biotech.
Uncover B2B Advertising That Performs
Mix enterprise intelligence and editorial excellence to achieve engaged professionals throughout 36 main media platforms.
The collaboration additionally consists of greater than $400m in milestone funds, in addition to royalties on any medicine permitted sooner or later.
MeiraGTx’s AAV-AIPL1 is in growth to deal with Leber congenital amaurosis kind 4 (LCA4), a extreme inherited retinal illness that’s attributable to genetic deficiency of aryl-hydrocarbon-interacting protein-like 1 (AIPL1).
AIPL1 is a protein vital for the functioning of the attention’s light-sensing pathway.
AAV-AIPL1 has already produced optimistic leads to a non-randomised examine performed within the UK, with outcomes revealed in The Lancet in February 2025. Knowledge from 4 of 11 youngsters enrolled within the examine, who had extreme retinal dystrophy as a result of AIPL1 mutation, demonstrated that the remedy improved visible acuity in handled eyes.
In its press launch asserting the Lilly collaboration, MeiraGTx stated that AAV-AIPL1 led to imaginative and prescient beneficial properties in all 11 handled youngsters, together with advantages in different areas of paediatric growth.
Andrew Adams, Lilly’s group vice-president of molecule discovery, stated: “Ophthalmology is an rising space of curiosity for Lilly. We’re excited to associate with MeiraGTx to carry transformative therapies to sufferers world wide affected by eye illnesses, beginning with AAV-AIPL1, which has proven the unprecedented capacity to revive imaginative and prescient in youngsters who have been born legally blind.”
In a quarterly report revealed in June 2025, MeiraGTx stated that it’s “getting ready the submission of an advertising and marketing authorisation software within the UK and a biologics license software within the US for AAV-AIPL1”. This was based mostly on discussions with the UK’s Medicines and Healthcare merchandise Regulatory Company (MHRA) and US Meals and Drug Administration (FDA) and the outcomes from the 11 sufferers.
Different ophthalmology property included within the deal are intravitreal capsids developed in-house at MeiraGTx and AI-generated promoters for particular cells within the retina. The biotech has additionally opened the door to Lilly for its riboswitch expertise, a platform that permits in-vivo manufacturing of a therapeutic protein or gene modifying nuclease.
Adams’ assertion that ophthalmology represents an “rising space of curiosity” for Lilly is supported by the cash the corporate has lately spent within the space. final month, Lilly outlaid $261.7m to accumulate Adverum Biotechnologies, an organization growing an intravitreal gene remedy for the remedy of moist age-related macular degeneration (AMD). Mixed with the MeiraGTx licensing deal, this implies Lilly has spent greater than half a billion {dollars} on gene therapies particularly in growth for eye illnesses.
This isn’t the one gene remedy space Lilly has focused in 2025. In April, the massive pharma firm signed a licensing deal price as much as $1.4bn for Sangamo Therapeutics’ neurology-targeting gene remedy. As well as, Lilly acquired RNA-based gene remedy developer Rznomics in Might 2025, and gene modifying associate Verve Therapeutics for $1.3bn a month later.
Lilly’s R&D push with the modality goes in opposition to the grain of huge pharma usually opting to retreat from the cell and gene remedy sector.
Earlier this month, Galapagos wound down its cell and gene remedy division after failing to promote the unit. Japanese pharma Takeda additionally deserted its cell remedy analysis, pivoting as a substitute in the direction of small molecules, biologics and antibody-drug conjugates (ADCs).
As well as, Gilead Sciences’ Kite Pharma terminated its cell remedy collaboration with Shoreline in September 2025, ending a analysis partnership valued at $2.3bn.
Cell & Gene Remedy protection on Pharmaceutical Expertise is supported by Cytiva.
Editorial content material is independently produced and follows the highest requirements of journalistic integrity. Subject sponsors usually are not concerned within the creation of editorial content material.
Join our each day information round-up!
Give your enterprise an edge with our main trade insights.
